# TargetingOne

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/targetingone

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.targetingone.com
- Total disclosed funding: $23M
- Latest round: Series B (Jan 7, 2021)
- Investors on record: 4

## About

Founded in 2015 and based in Beijing, China, TargetingOne is a biotech company that focuses on the development of micro-droplet digital PCR systems and in vitro diagnostic reagents. It has service centres in Hunan, Fujian, Guangdong, Henan, Liaoning, and Shanghai. The company acquired certifications such as ISO9001 and ISO14001. It has obtained more than 100 patents. In April 2024, the company raised CNY 100 million in strategic investment from new investor State-Owned Capital Operation and Management Centre of Beijing.

The company mainly provides equipment, reagents, and consumables. The equipment includes digital PCR platforms, nucleic acid extraction instruments, and PCR amplification instrument. Reagents include human EGFR (Epidermal Growth Factor Receptor) gene mutation detection and virus rapid extraction. Consumables include disposable virus sampling tubes and digital PCR consumables. The company's products are used in fields such as tumours, genetic diseases and infectious diseases.

The company generates revenue by providing droplet digital PCR (Polymerase Chain Reaction), droplet technology platform, non-invasive prenatal testing, and liquid biopsy.

The company will use the strategic investment to accelerate the company's clinical registration of digital PCR and molecular POCT series reagent products.

## Funding rounds

- Series B, Jan 7, 2021, $23M — Lilly Asia Ventures, Hillhouse Investment, China Growth Capital, Silu Huachuang Capital

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series B
- Silu Huachuang Capital (https://capitalatlas.ai/funds/silu-huachuang-capital) — Series B